| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Thymidylate synthase, dihydropyrimidine dehydrogenase, orotate phosphoribosyltransferase mRNA and protein expression levels in solid tumors in large scale population analysis.
|
Int J Mol Med
|
2008
|
1.00
|
|
2
|
A novel mutant allele of the CYP2A6 gene (CYP2A6*11 ) found in a cancer patient who showed poor metabolic phenotype towards tegafur.
|
Pharmacogenetics
|
2002
|
0.98
|
|
3
|
Population study of expression of thymidylate synthase and dihydropyrimidine dehydrogenase in patients with solid tumors.
|
Int J Mol Med
|
2003
|
0.90
|
|
4
|
Antimetastatic and anticancer activity of S-1, a new oral dihydropyrimidine-dehydrogenase-inhibiting fluoropyrimidine, alone and in combination with paclitaxel in an orthotopically implanted human breast cancer model.
|
Int J Oncol
|
2004
|
0.87
|
|
5
|
Identification of human liver cytochrome P450 isoforms involved in autoinduced metabolism of the antiangiogenic agent (Z)-5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-propanoic acid (TSU-68).
|
Drug Metab Dispos
|
2008
|
0.84
|
|
6
|
Decrease in plasma concentrations of antiangiogenic agent TSU-68 ((Z)-5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-propanoic acid) during oral administration twice a day to rats.
|
Drug Metab Dispos
|
2007
|
0.83
|
|
7
|
Functional characterization of single nucleotide polymorphisms with amino acid substitution in CYP1A2, CYP2A6, and CYP2B6 found in the Japanese population.
|
Drug Metab Pharmacokinet
|
2004
|
0.80
|
|
8
|
Time-dependent induction of rat hepatic CYP1A1 and CYP1A2 expression after single-dose administration of the anti-angiogenic agent TSU-68.
|
Drug Metab Pharmacokinet
|
2008
|
0.78
|
|
9
|
Formation pathways of gamma-butyrolactone from the furan ring of tegafur during its conversion to 5-fluorouracil.
|
Drug Metab Dispos
|
2010
|
0.78
|
|
10
|
Pharmacokinetic modeling of species-dependent enhanced bioavailability of trifluorothymidine by thymidine phosphorylase inhibitor.
|
Drug Metab Pharmacokinet
|
2004
|
0.78
|
|
11
|
Effect of dimethylnitrosamine-induced liver dysfunction on the pharmacokinetics of 5-fluorouracil after administration of S-1, an antitumour drug, to rats.
|
J Pharm Pharmacol
|
2009
|
0.77
|
|
12
|
Involvement of concentrative nucleoside transporter 1 in intestinal absorption of trifluorothymidine, a novel antitumor nucleoside, in rats.
|
J Pharmacol Exp Ther
|
2011
|
0.77
|
|
13
|
Distribution of (7alpha)-21-[4-[(diethylamino) methyl]-2-methoxyphenoxy]-7-methyl-19-norpregna-1,3,5(10)-trien-3-ol-20-[14C]2-hydroxy-1,2,3-propanetricarboxylate ([14C]TAS-108) and its metabolites after single oral administration to rats bearing 7,12-dimethylbenz(alpha)anthracene-induced mammary tumor.
|
Drug Metab Dispos
|
2005
|
0.75
|
|
14
|
TSU-16, (Z)-3-[(2,4-dimethylpyrrol-5-yl)methylidenyl]-2-indolinone, is a potent activator of aryl hydrocarbon receptor and increases CYP1A1 and CYP1A2 expression in human hepatocytes.
|
Chem Biol Interact
|
2010
|
0.75
|